GOVX
GeoVax Labs, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
GeoVax Labs, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
GeoVax Labs, Inc.
0.16
0.00 · +0.61%
post 0.17 +3.05%
No other changes.
No other changes.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for GeoVax Labs, Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for GeoVax Labs, Inc..
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Apr 15 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
−26.73%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Jane Street | $400,399 | 63.91% | new |
| HRT Financial | $161,000 | 25.70% | new |
| Geodeindex-like | $26,811 | 4.28% | −41.48% |
| Two Sigma Securities | $13,566 | 2.17% | new |
| Vanguard Fiduciary Trustindex-like | $6,436 | 1.03% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Jane Street | $400,399 | 63.91% | new |
| HRT Financial | $161,000 | 25.70% | new |
| Geodeindex-like | $26,811 | 4.28% | −41.48% |
| Two Sigma Securities | $13,566 | 2.17% | new |
| Vanguard Fiduciary Trustindex-like | $6,436 | 1.03% | 0.00% |
Largest filed tie
—
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.
—
—